$SCNX

Scienture Holdings, Inc.

Scienture Holdings, through its wholly owned subsidiary Scienture LLC, is a specialty pharmaceutical company focused on developing and commercializing treatments for cardiovascular and central nervous system diseases. Its products include Arbli, an FDA-approved losartan potassium oral suspension for hypertension, and REZENOPY, a licensed naloxone nasal spray for opioid overdose. Its development pipeline includes candidates for migraine and cluster headaches, catheter occlusion, and postsurgical pain. Scienture sells pharmaceutical products and plans to market them in the U.S. through its own sales and marketing operation, supported by a contract sales organization. It also seeks strategic collaborations to commercialize products outside the U.S. The company relies on third-party manufacturers for production. Scienture LLC’s principal executive offices are in Commack, New York.

0
1
1

No SEC Form 4 filings for $SCNX in the last 30 days.

See all $SCNX insider activity →
Low

SCIENTURE HOLDINGS, INC. (SCNX) Q3 Revenue Rose 113% YoY to $1.25M

Scienture Holdings reported Q3 2026 revenue of $1.25M, up 113% YoY and 265% sequentially. The growth was driven by the August launch of REZENOPY, which generated $925K in net product revenue. The company also cited sales of Arbli as a contributing factor.

SCNX Q3'26 Earnings: EPS estimate is (1.57) USD

Scienture Holdings (SCNX) will report Q3'26 earnings on November 12. Analysts expect revenue of $1.22M and an EPS loss of $1.57. Details are available on the company's Financials page.

SCNX Q3'26 Earnings: revenue estimate is 1.22M USD

Scienture Holdings (SCNX) will report Q3'26 earnings on November 12. Analysts expect revenue of 1.22M USD and an EPS of (1.57) USD. Details are available on the company's financials page.

SCNX sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 2 news stories mentioning SCNX (Scienture Holdings, Inc.). Coverage has skewed bearish: 0 bullish, 1 neutral, and 1 bearish.

Recent SCNX coverage spans earnings, corporate actions and financial news.

What's driving SCNX

AlphAI scores every news story that mentions SCNX with an AI model for sentiment and relevance, and aggregates insider trades from Scienture Holdings, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $SCNX

Score
$SCNXLowShareholder vote

Scienture Holdings, Inc. (SCNX): Submission of Matters to a Vote of Security Holders

Scienture Holdings, Inc. (SCNX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. On October 28, 2026, Scienture Holdings, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “2026 Annual Meeting”) virtually via a live webcast. The Company’s stockholders voted on four proposals

$SCNXMedEarnings

Scienture Holdings, Inc. (SCNX): Continued Arbli™ sales growth, combined with REZENOPY™ commercial launch in August 2026 and initial wholesale shipments, drives significant sequential…

Scienture Holdings, Inc. (SCNX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Continued Arbli ™ sales growth, combined with REZENOPY ™ commercial launch in August 2026 and initial wholesale shipments, drives significant sequential revenue growth Arbli ™ wholesale unit sales increased 74% sequentially, with recent institutional formulary additi

$SCNXMedStock split· reverse

Scienture Holdings, Inc. Announces Reverse Stock Split

Scienture Holdings, Inc. (SCNX) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Scienture Holdings, Inc. Announces Reverse Stock Split COMMACK, NY, September 30, 2026 (GLOBE NEWSWIRE) – SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhance

SCIENTURE Announces Arbli™ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals

Scienture Holdings (SCNX) announced that its Arbli™ (losartan potassium) Oral Suspension has been added to the formularies of three leading U.S. pediatric medical centers. Arbli™ addresses a $219 million U.S. losartan market, with 72 million prescriptions annually. The company reported increasing wholesale orders and sees significant growth potential, especially in pediatric care.

Related tickers